Trial Profile
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 19 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Apr 2023 Status changed from suspended to recruiting.